Fusion protein · Antagonist of LAIR-1 (CD305) (LAIR1) · developed by NextCure
NC410 is a fusion protein based on leukocyte-associated immunoglobulin-like receptor 2 (LAIR-2), a high-affinity collagen receptor. It binds collagen, blocking collagen binding to the inhibitory receptor LAIR-1 on T cells and dendritic cells. It is being studied in pancreatic cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06941857 | Phase 2 | Pancreatic Cancer | Recruiting | NXTC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pancreatic Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.
See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NXTC catalysts and pipeline →